Home » Stocks » Aclaris Therapeutics

Aclaris Therapeutics, Inc. (ACRS)

Stock Price: $3.95 USD -0.35 (-8.14%)
Updated Oct 26, 2020 1:02 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 168.76M
Revenue (ttm) 5.53M
Net Income (ttm) -101.10M
Shares Out 42.72M
EPS (ttm) -2.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $3.95
Previous Close $4.30
Change ($) -0.35
Change (%) -8.14%
Day's Open 4.30
Day's Range 3.92 - 4.34
Day's Volume 167,647
52-Week Range 0.70 - 5.04

More Stats

Market Cap 168.76M
Enterprise Value 111.82M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 42.72M
Float 32.71M
EPS (basic) -2.43
EPS (diluted) -2.43
FCF / Share -1.49
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 691,504
Short Ratio 2.86
Short % of Float 2.11%
Beta 1.29
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 30.51
PB Ratio 3.69
Revenue 5.53M
Operating Income -67.30M
Net Income -101.10M
Free Cash Flow -62.60M
Net Cash 56.93M
Net Cash / Share 1.33
Gross Margin -1,150.08%
Operating Margin -1,216.85%
Profit Margin -1,827.80%
FCF Margin -1,131.87%
ROA -26.70%
ROE -74.47%
ROIC -189.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.50*
(13.92% upside)
Low
3.50
Current: $3.95
High
5.00
Target: 4.50
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue4.236.151.68----
Revenue Growth-31.28%265.48%-----
Gross Profit0.171.820.48----
Operating Income-111-84.78-54.36-48.57-20.67-8.53-5.26
Net Income-161-133-68.52-48.08-20.56-8.52-5.24
Shares Outstanding41.3232.9128.1021.426.111.721.08
Earnings Per Share-3.90-4.03-2.44-2.25-3.79-6.15-6.45
Operating Cash Flow-96.45-101-54.66-34.60-20.37-7.64-4.92
Capital Expenditures-1.61-1.36-1.24-0.23-0.51-0.42-
Free Cash Flow-98.06-102-55.90-34.84-20.88-8.05-4.92
Cash & Equivalents75.0216819413784.8716.13-
Total Debt0.6430.06-----
Net Cash / Debt74.3813819413784.8716.13-
Assets98.3027624417694.0817.38-
Liabilities28.3960.4418.256.601.561.46-
Book Value69.9121522516992.52-20.76-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aclaris Therapeutics, Inc.
Country United States
Employees 75
CEO Neal S. Walker

Stock Information

Ticker Symbol ACRS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ACRS
IPO Date October 7, 2015

Description

Aclaris Therapeutics, a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.